Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.SSE: 603707

Announcement on Implementation of Dividend Distribution for 2025

Jun 3, 2026 · Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jun 3, 2026 · 4 pages · Chinese

On 6ix: 6ix.com/news/announcement-on-implementation-of-dividend-distribution-for-2025-452

Release

Announcement on Implementation of Dividend Distribution for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. on 6ix

Earlier from Nanjing King-friend Biochemical Pharmaceutical

Announcement on Resolutions of the 1st Meeting of the 6th Board of DirectorsMay 21
Announcement on Implementation Result of Shares Repurchase and Share ChangesMay 12
Announcement on Progress in Repurchasing SharesMay 7
Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026May 6
Announcement on Proposing of Purchasing Liability Insurance for the Company and Directors, and Senior Management MembersApr 30

Later from Nanjing King-friend Biochemical Pharmaceutical

Announcement on the Subsidiary's Receipt of the U.S. FDA Approval for the Manufacturing Site Transfer Registration of Desmopressin Acetate InjectionJul 4
Announcement on Obtaining the Drug Registration Approval for Propofol Emulsion Injection by the National Medical Products AdministrationJul 7
Announcement on the U.S. FDA Approval of the Subsidiary's Insulin Aspart InjectionJul 28
Announcement on Change in Accounting PoliciesAug 28
Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Adalimumab InjectionSep 2

All Nanjing King-friend Biochemical Pharmaceutical news releases

Follow Nanjing King-friend Biochemical Pharmaceutical into a list and get an email when it puts out news.

Follow Nanjing King-friend Biochemical Pharmaceutical